Entrada Therapeutics Inc. (TRDA)
12.50
-0.87 (-6.51%)
At close: Jan 14, 2025, 3:59 PM
undefined% (undefined)
| Bid | 5 |
| Market Cap | 467.75M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.44 |
| PE Ratio (ttm) | 8.68 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 19.85 |
| Volume | 155,895 |
| Avg. Volume (20D) | 119,983 |
| Open | 13.44 |
| Previous Close | 13.37 |
| Day's Range | 12.35 - 13.67 |
| 52-Week Range | 11.35 - 21.79 |
| Beta | undefined |
About TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also eng...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 29, 2021
Employees 177
Stock Exchange NASDAQ
Ticker Symbol TRDA
Website https://www.entradatx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for TRDA stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 124.00% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Entrada Therapeutics Inc. is scheduled to release its earnings on Mar 12, 2025,
before market opens.
Analysts project revenue of $12.92M, reflecting a -69.13% YoY shrinking and earnings per share of -0.66, making a 127.59% increase YoY.
Analysts project revenue of $12.92M, reflecting a -69.13% YoY shrinking and earnings per share of -0.66, making a 127.59% increase YoY.
5 months ago ·
Source
+11.26%
Entrada Therapeutics shares are trading higher. Th...
Unlock content with
Pro Subscription
